OCGN earnings: next report 2026-07-30, real EPS beat/miss history, analyst consensus Buy, P/E -5.54. Updated 2026-07-23.
Ocugen (OCGN) Research Hub
Ocugen (OCGN) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 1.02 USD (-4.67%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -5.54, market cap 0.44B. This hub links to the full technical, earnings and options research available for OCGN.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 1.02 USD (-4.67%) |
| 52-week range | 1.01 USD – 1.69 USD |
| Trend regime | Range |
| 14-day RSI | 34.1 (Bearish) |
| Trailing P/E | -5.54 |
| Market cap | 0.44B |
| Dividend yield | 0.00% |
| Next earnings | 2026-07-30 |
Available research for OCGN
Covered Call on OCGN: how it works, illustrative setup around the real 1.02 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on OCGN: how it works, illustrative setup around the real 1.02 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on OCGN: how it works, illustrative setup around the real 1.02 USD price, max profit/loss, breakeven and when to use it. Educational.
OCGN technical analysis: range, last 1.02 USD, RSI 34.1, 52w range 1.01 USD–1.69 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is OCGN in?
Ocugen (OCGN) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is OCGN in an uptrend or downtrend?
As of 2026-09-11, OCGN is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is OCGN's trailing P/E ratio?
OCGN's trailing P/E is -5.54, with a market cap of 0.44B. See the earnings research page for full valuation detail.
When does OCGN next report earnings?
OCGN is next scheduled to report earnings on 2026-07-30, with a consensus EPS estimate of -0.05 USD.